BADBIR / Clinicians / Eligibility

Eligibility

This page outlines the full eligibility criteria for registering patients into BADBIR, including requirements for paediatric patients, all patients, and those starting biologic, conventional, or small molecule therapies.

Clinicians can use the information below to determine whether a patient qualifies for inclusion and to understand any cohort‑specific conditions.

You can download the latest eligibility poster from the Useful Resources Page.

Paediatric patients

If the patient is under the age of 16 at the time of consent and is starting any systemic treatment for psoriasis — even if we are not currently recruiting for that drug in adults — they are eligible for BADBIR.

Patients starting on a conventional treatment are not required to meet the DLQI score criteria.

If you have any queries, please contact us:

All patients

  • Must have a diagnosis of chronic plaque or generalised pustular psoriasis.
  • Must provide written informed consent.
  • Therapy must be ongoing at the time of consent.
  • Must have started or switched therapy within six months of the date of consent.
  • PASI and DLQI must be recorded within six months prior to therapy starting.
  • Patients should be added to the BADBIR database within six months of consenting.
Biologic Cohort

No minimum PASI or DLQI score is required, but values must be taken within six months prior to therapy start so we have a baseline measure.

Biologic therapies currently included:

Biologic therapies Amgevita (adalimumab)
Bimzelx (bimekizumab)
Cosentyx (secukinumab)
Hulio (adalimumab)
Humira (adalimumab)
Hyrimoz (adalimumab)
Idacio (adalimumab)
Ilumetri (tildrakizumab)
Skyrizi (risankizumab)
Spevigo (spesolimab)
Stelara (ustekinumab)
Taltz (ixekizumab) – recruitment ended 31 July 2025
Tremfya (guselkumab)
Yuflyma (adalimumab)

For previously recruited biologics, see: News Page.

Conventional Cohort

p>The patient must be biologic‑naïve.

  • PASI ≥ 10 and DLQI ≥ 11 at therapy start, regardless of psoriasis type.
  • No minimum PASI/DLQI if switching between conventional therapies with < 3‑month gap.
  • If switching or adding a new conventional therapy, the dermatologist must confirm a history of moderate–severe psoriasis.
  • From Amendment 14 (08/05/2025), the conventional therapies we recruit for are:
Conventional therapies Acitretin (paediatric or GPP only)
Ciclosporin (paediatric or GPP only)
Fumaric acid esters (paediatric only)
Hydroxycarbamide (paediatric only)
Methotrexate
Systemic oral PUVA – not bath PUVA (paediatric only)
Non‑Biologic Small Molecule Cohort

The patient must be biologic‑naïve unless commencing Sotyktu (deucravacitinib).

  • Biologic‑naïve starting Sotyktu → small molecule cohort.
  • Biologic‑exposed starting Sotyktu → biologic cohort.
  • No minimum PASI/DLQI score required, but values must be taken within six months prior.
  • Small molecule therapies currently included:
Small molecule therapies Skilarence (dimethyl fumarate) – recruitment ended 31 July 2023
Sotyktu (deucravacitinib)
Guide on registering a new patient

If you are unsure about eligibility, please contact the BADBIR office.